Bleomycin, vincristine, cisplatin/bleomycin, etoposide, cisplatin chemotherapy: An alternating, dose intense regimen producing promising results in untreated patients with intermediate or poor prognosis malignant germ-cell tumours

British Journal of Cancer

Volumn 90, Issue 3, 2004, Pages 601-606

  Anthoney, D A ^a,d   McKean, M J ^a   Roberts, J T ^b   Hutcheon, A W ^c   Graham, J ^a   Jones, W ^d   Paul, J ^a   Kaye, S B ^a  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

^b Northern Centre for Cancer Treatment   (United Kingdom)

^c ABERDEEN ROYAL INFIRMARY   (United Kingdom)

^d Northern and Yorkshire Clinical Trials and Research Unit   (United Kingdom)

Author keywords

Chemotherapy; Dose intense; Malignant germ cell tumour; Poor prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; BEP PROTOCOL; BLEOMYCIN; CISPLATIN; COB PROTOCOL; ETOPOSIDE; IFOSFAMIDE; VINCRISTINE;

ADOLESCENT; ADULT; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; FOLLOW UP; GERM CELL TUMOR; GRANULOCYTOPENIA; HEARING LOSS; HUMAN; IATROGENIC DISEASE; INFERTILITY; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG FIBROSIS; LUNG TOXICITY; MALE; MOTOR NEUROPATHY; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEOPLASM; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OLIGOSPERMIA; OTOTOXICITY; PATHOLOGY; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; SKIN TOXICITY; STATISTICAL SIGNIFICANCE; SURVIVAL; THROMBOCYTOPENIA; TINNITUS; TREATMENT OUTCOME; VASOSPASM;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAMUSCULAR; MIDDLE AGED; NEOPLASMS, GERM CELL AND EMBRYONAL; NEUTROPENIA; PROGNOSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 1542299240     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601528     Document Type: Article

References (25)

1. Beyer J, Kingreen D, Krause M, Schleicher J, Schwaner I, Scwella N, Huhn D, Siegert W (1997) Long term survival of patients with recurrent or refractory germ cell tumours after high dose chemotherapy. Cancer 79: 161-168
2. Bokemeyer C, Beyer J, Metzner B, Ruther U, Harstrick A, Weissbach L, Kohrmann U, Verbeek W, Schmoll HJ (1996) Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer. Ann Oncol 7: 31-34
3. Bokemeyer C, Harstrick A, Beyer J, Metzner B, Ruther U, Hartmann JT, Holstein K, Derigs HG, de Wit R, Casper J, Schoffski P, Kuhrer I, Illiger HJ, Kempf B, Reichle A, Foller A, Hossfeld DK, Fischer JT, Berdel WE, Gerhartz HH, Kirchenr H, Pfluger KH, Ostermann H, Kanz L, Schmoll HJ (1998) The use of dose intensified chemotherapy in the treatment of metastatic nonseminomatous testicular germ cell tumours. German testicular cancer study group. Semin Oncol 25: 24-32
4. Bokemeyer C, Gerl A, Schoffski P, Harstrick A, Niederle A, Beyer J, Casper J, Schmoll HJ, Kanz L (1999b) Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer. J Clin Oncol 17: 512-516
5. Bokemeyer C, Kollmannsberger C, Meisner C, Harstrick A, Beyer J, Metzner B, Hartmann JT, Schmoll HJ, Einhorn L, Kanz L, Nichols C (1999a) First-line high-dose chemotherapy compared with standard dose PEB/VIP chemotherapy in patients with advanced germ cell tumours: A multivariate and matched-pair analysis. J Clin Oncol 17: 3450-3456
6. Bosl GJ (1998) Germ cell tumours: there is still plenty to learn. J Clin Oncol 16: 1244-1247
7. Bower M, Newlands ES, Holden L, Rustin GJS, Begent RHJ (1997) Treatment of men with metastatic non-seminomatous germ cell tumours with cyclical POMB/ ACE chemotherapy. Ann Oncol 8: 477-483
8. Chevreau C, Droz JP, Pico JL, Biron P, Kerbrat P, Cure H, Heron JF, Chevallier B, Fargeot P, Kramer A (1993) Early intensified chemotherapy with autologous bone marrow transplantation in first line treatment of poor risk non-seminomatous germ cell tumours. Preliminary results of a French randomised trial. Eur Urol 23: 213-218
9. Christian JA, Huddart RA, Norman A, Mason M, Fossa S, Aass N, Nicholl EJ, Dearnaley DP, Horwich A (2003) Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumours. J Clin Oncol 21: 871-877
10. Cullen MH, Harper PG, Woodroffe CM, Kirkbride P, Clarke J (1988) Chemotherapy for poor risk germ cell tumours. An independent evaluation of the POMB/ACE regime. Br J Urol 62: 454-460
11. De Bono JS, Paul J, Simpson A, Anthoney A, Kirk D, Underwood M, Graham J, Kaye SB (2000) Improving the outcome of salvage treatment for non-seminomatous germ cell tumours (NSGCT). Br J Cancer 83: 426-430
12. Decatris MP, Wilkinson PM, Welch RS, Metzner M, Morgenstern GR, Dougall M (2000) High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: an effective first-line therapy with minimal toxicity. Ann Oncol 11: 427-434
13. de Wit R, Louwerens M, de Mulder P, Verweij J, Rodenhuis S, Schornagel J (1999) Management of intermediate prognosis germ-cell cancer: results of a phase I/II study of Taxol-BEP. Int J Cancer 83: 831-833
14. de Wit R, Roberts JT, Wilkinson PM, de Mulder PH, Mead GM, Fos SD, Cook P, de Prijck L, Stenning S, Collette L (2001) Equivalence of three or four cycles of bleomycin, etoposide and cisplatin chemotherapy and of a 3-or 5-day schedule in good prognosis germ cell cancer: a randomised study of the European Organisation for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 19: 1629-1640
15. Einhorn LH, Stender MJ, Williams SD (1999) Phase II trial of gemcitabine in refractory germ cell tumours. J Clin Oncol 17: 509-511
16. Germa JR, Garcia del Muro X, Tabernero JM, Sanchez M, Aparicio J, Alloa E, Barnades A (1999) BOMP/EPI intensive alternating chemotherapy for IGCCC poor prognosis germ cell tumours: the Spanish Germ Cell Cancer Group experience. Ann Oncol 10: 289-293
17. Horwich A, Brada M, Nicholls J, Jay G, Hendry WF, Dearnaley D, Peckham MJ (1989) Intensive induction chemotherapy for poor risk non-seminomatous germ cell tumours. Eur J Cancer Clin Oncol 25: 177-184
18. Horwich A, Mason M, Fossa S, Mead GM, Huddart R, Nicholls J, Norman A, Dearnaley DP (1997) Accelerated Induction chemotherapy (C-BOP-BEP) for poor and intermediate prognosis germ cell tumours (GCT). ASCO Proc 16: 319A (Abstract) #1137
19. Husband DJ, Green JA (1992) POMB/ACE chemotherapy in non-seminomatous germ cell tumours: Outcome and importance of dose intensity. Eur J Cancer 28: 86-91
20. International Germ Cell Cancer Collaborative Group (1997) International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 15: 594-603
21. Kaye SB, Mead GM, Fossa S, Cullen M, de Wit R, Bodrogni I, van Groeningen C, Sylvester R, Collette L, Stenning S, De Prijck L, Lallemand E, de Mulder P (1998) Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic non-seminomatous germ cell tumour: a randomised Medical Research Council/ European Organisation for Research and Treatment of Cancer study. J Clin Oncol 16: 692-701
22. Lewis CR, Fossa SD, Mead G, ten Bokkel Huinink W, Harding MJ, Mill L, Paul J, Jones WG, Rodenburg CJ, Cantwell B (1992) BOP/VIP - a new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumours. Ann Oncol 2: 203-211
23. Motzer RJ, Bajorin DF, Schwartz LH, Hutter HS, Bosl GJ, Scher HI, Lyn P, Fischer P (1994) Phase II trial of paclitaxel shows antitumour activity in patients with previously treated germ cell tumours. J Clin Oncol 12: 2277-2283
24. Motzer RJ, Mazumdar M, Bajorin DF, Bosl GJ, Lyn P, Vlamis V (1997) High-dose carboplatin, etoposide and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor risk germ cell tumours. J Clin Oncol 15: 2546-2552
25. Ozols RF, Deisseroth AB, Javadpour N, Barlock A, Messerschmidt G, Young RC (1983) Treatment of poor prognosis nonseminomatous testicular cancer with a 'high-dose' platinum combination chemotherapy regimen. Cancer 51: 1803-1807